-
cover
-
general dashboard
-
timeline + medications
-
new appointment
-
manage medications
...is the percentage of female representation over 86 randomized control trials in healthcare/medicine-based studies (merone, 2022). that seems an awful lot less than the 50% of the population women make up.
sexism in healthcare
“my sister died because doctors didn’t believe her.” (u/anonymous poster, 2023).
clinical trials and device studies routinely enroll far fewer women than men, leaving the evidence that shapes care biased toward male bodies. for example, device trials randomized a median of about 33% women in a recent systematic review. (karny epstein et al., 2024).
this male-centred evidence base produces concrete harms. women’s heart-attack presentations are more varied and are more often missed/misdiagnosed, which could delay treatment and worsen health outcomes (ducharme, 2018).
drug safety and dosing can also suffer. the u.s. food and drug administration lowered recommended zolpidem (ambien) doses for women after post-market evidence showed greater next-day impairment at formerly recommended doses (u.s. food and drug administration, 2013).
in short: under-enrollment + lack of sex-disaggregated analysis + clinicians dismissing women’s symptoms combine to make routine diagnoses, guidelines, and 'common sense' less reliable for women (karny epstein et al., 2024; ducharme, 2018).
medisyn — an 'm.d.' for an 'ms.'!
'medisyn' is an absurd play on words for the name 'madison', '[med]icine', and 'sync.'
medisyn is a medical assessment tool that harnesses machine learning, computer vision, hardware, web scraping, and software systems to support practicing medical professionals in creating unbiased, accurate medical counsel with a focus on women, afab individuals, and intersex individuals.
aimed as an interface available for medical practitioners in managing the information of their patients, medisyn integrates an mcp that gathers context on patient information (i.e. symptoms, quantitative health measurements) and research articles that focus on women as participants. this results in a built-in counsel for practitioners to reference.
putting the 'feat' in features
🩺 clinician console Patient roster, vitals dashboard, and interactive timeline for recording symptoms, medications, and diagnoses.
🧠 ai-assisted diagnosis language-model layer trained on research emphasizing women and afab participants. It suggests likely conditions, red-flags overlooked presentations (e.g., non-chest-pain heart attacks), and links each inference to its citation source.
💊 medication management prescription tracker from the perspective of a general practitioner.
📸 computer-vision telemetry webcam integration for optional face-based vitals or expression-of-pain capture, processed locally / via encrypted Python pipeline.
🎨 adaptive accessibility modes high-contrast, colour-blind-safe, dyslexia-friendly, reduced-motion, and large-text themes.
📊 evidence-based context engine back-end crawler (Express + Mongoose) that surfaces sex-disaggregated clinical trials and female-focused research directly inside a patient’s note.
☁ persistent data layer mongodb schema with optimistic updates + async fetching.
next up for medisyn
🪪 biometric identifiers - facial, voice, or rfid/nfc patient id; qr health passports for instant record access.
⚙️ hardware integration -bluetooth vitals (bp cuffs, oximeters, ecgs, glucometers), imaging uploads, and smart-stethoscope input.
⌚ wearables & telemetry - sync data from apple health / fitbit / hospital monitors for accurate vitals.
🔗 interoperability - full smart-on-fhir support + provincial registry integration.
💬 clinical ux - speech or sketch-based symptom input!
end goal is a healthcare ecosystem where clinical decision support reflects everyone’s physiology, and where adaptive design makes equitable+inclusive medicine the default. •ᴗ•
citations
Merone L, Tsey K, Russell D, Nagle C. Sex Inequalities in Medical Research: A Systematic Scoping Review of the Literature. Womens Health Rep (New Rochelle). 2022 Jan 31;3(1):49-59. doi: 10.1089/whr.2021.0083. Erratum in: Womens Health Rep (New Rochelle). 2022 Mar 16;3(1):344. doi: 10.1089/whr.2021.0083.correx. PMID: 35136877; PMCID: PMC8812498.
Karny Epstein, N., Yahav, Y., Harpaz, R., Abo-Molhem, A., Tau, L., et al. (2024). Women’s representation in randomized clinical trials evaluating FDA-supervised medical devices: A systematic review. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.1011
Ducharme, J. (2018, February 21). Here’s why doctors often miss heart attack symptoms in women. Time. https://time.com/5168411/women-heart-attack-symptoms/
U.S. Food and Drug Administration. (2013, May 14). FDA approves new label changes and dosing for zolpidem products and dosing for women. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-new-label-changes-and-dosing-zolpidem-products-and
u/anonymous poster. (2023, July). My sister died because doctors didn’t believe her and I still feel so much rage [Online forum post]. Reddit. https://www.reddit.com/r/TwoXChromosomes/comments/152ivtk/my_sister_died_because_doctors_didnt_believe_her/
Log in or sign up for Devpost to join the conversation.